

Designing a Patient-Centered Value Framework to Guide Shared Decision-Making in Oncology: Why, What, and How?

Jalpa A. Doshi, PhD

Professor, University of Pennsylvania Perelman School of Medicine

Director, Economic Evaluations Unit, Center for Evidence-based Practice

Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics

Senior Fellow, Leonard Davis Institute of Health Economics

University of Pennsylvania

ISPOR 23rd Annual International Meeting

May 21, 2018



1



Unprecedented pharmacological breakthroughs in oncology over the past decade

The screenshot shows two news articles. The left article is from the Los Angeles Times, dated August 30, 2017, titled "Hailing a breakthrough in fighting cancer, FDA approves gene therapy that functions as a 'living drug'". The right article is from CNBC, titled "Cancer research breakthrough shows a better way to predict drugs that will work". Below the CNBC article, there is a small text snippet: "A new study used lab-engineered microtumors to predict if cancer drugs will work in patients. disease treatments and less patient side effects."



New report: Decade of breakthroughs in cancer




Emma Van Hook | June 2, 2016 | SHARE THIS



High costs of these novel anticancer drugs has placed considerable strain on the U.S. health care system

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval
1965-2017




Source: Peter B. Bach, MD, Memorial Sloan Kettering Cancer Center



Specialty tiers, coinsurance, and high deductible health plans mean patients are not immune to prices

Risk-adjusted Rates of Patient Reversal, Delay, and Abandonment of Oral Anticancer Prescription



Doshi, JA, Li P, Huo H, Pettit A, Armstrong KA. Association of Patient Out-of-Pocket Costs with Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. Journal of Clinical Oncology 35, Dec. 2017.



In response, U.S. clinical organizations have developed value frameworks to help patients and providers



What did these frameworks set out to do?

- Help guide shared patient/physician decision making for cancer treatment choices
- Integrate cost and value into treatment planning



In response, U.S. clinical organizations have developed value frameworks to help patients and providers



What did these frameworks set out to do?

- Help guide shared patient/physician decision making for cancer treatment choices
- Integrate cost and value into treatment planning

While these efforts are laudable, these frameworks have attracted a variety of criticisms.



Key questions to be addressed by the panel

- **WHY** do we need a more patient-centered framework?
- **WHAT** is important to patients, and how can we develop and implement a decision tool that truly meets the goals and priorities of individuals in daily clinical practice?
- **HOW** can we develop a scoring approach to help inform decision-making based on the various factors?

Today's Panel



Henry Glick, PhD, Professor of Medicine, Perelman School of Medicine; Professor of Health Care Systems, Wharton School; University of Pennsylvania, Philadelphia, PA, USA



Ellen Miller Sonet, JD, MBA, Chief Strategy and Alliance Officer, CancerCare, New York, NY



Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA